anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Ascites syndrome (AS) in broiler chickens, also known as pulmonary arterial hypertension (PAH), is a significant disease in the poultry industry. It is a nutritional metabolic disease that is closely associated with hypoxia-inducible factors and rapid growth. The rise in pulmonary artery pressure is a crucial characteristic of AS and is instrumental in its development. Hypoxia-inducible factor 1α (HIF-1α) is an active subunit of a key transcription factor in the oxygen-sensing pathway. HIF-1α plays a vital role in oxygen homeostasis and the development of pulmonary hypertension. Studying the effects of HIF-1α on pulmonary hypertension in humans or mammals, as well as ascites in broilers, can help us understand the pathogenesis of AS. Therefore, this review aims to (1) summarize the mechanism of HIF-1α in the development of pulmonary hypertension, (2) provide theoretical significance in explaining the mechanism of HIF-1α in the development of pulmonary arterial hypertension (ascites syndrome) in broilers, and (3) establish the correlation between HIF-1α and pulmonary arterial hypertension (ascites syndrome) in broilers. HIGHLIGHTSExplains the hypoxic mechanism of HIF-1α.Linking HIF-1α to pulmonary hypertension in broilers.Explains the role of microRNAs in pulmonary arterial hypertension in broilers.
The invention provides an erythropoietin (EPO) variant-Fc fusion protein. An erythropoietin (EPO) variant is an EPO extracellular region complete sequence, and disappearance of the hematopoietic activity can be caused by directional mutation of the EPO extracellular region complete sequence and hematopoietic function associated amino acids. An Fc fragment includes a hinge region, a CH2 region and a CH3 region. The EPO variant and Fc sequence are fused by direct fusion or by connecting sequences. The EPO extracellular region complete sequence is selected from EPO of human or other animals. The Fc fragment is selected from IgG, IgM, IgD, IgA of human or other animals or sub types of the IgG, IgM, IgD, IgA of human or other animals, and the Fc fragment is selected from natural type Fc or mutant type Fc which is changed by combination of associated amino acids with a receptor and/or a complement. The application of the EPO variant-Fc fusion protein includes promotion of neural stem cell regeneration, and applications in the manufacture of drugs for prevention and treatment of nerve cell injury. The hematopoietic activity of the EPO variant-Fc fusion protein is substantially disappeared, so that the EPO variant-Fc fusion protein has tissue protection activity, namely, nerve cell regeneration activity, and also has a long-term in-vivo application half-life period similar with that of the use of antibodies.
An actuator, with two independent degrees of freedom, rotates a stage about an axis and moves the stage along the axis, the range of motion defining a cylinder or cylindrical section. The stage is mounted on a hollow cylindrical plunger fitting in an annular well. A bearing allows the plunger to move axially and rotationally, in the preferred embodiment the bearing is an air bearing. The plunger has an array of permanent magnets on its external cylindrical face opposite coils in the well. Equal numbers of oppositely-polarized permanent magnets are arranged in a regular cylindrical pattern at 50% packing density forming rings and columns of like-polarity magnets, the rings of one polarity alternating with rings of opposite polarity and the columns of one polarity alternating with columns of opposite polarity. A set of Z-axis coils (for axial movement) curve around the plunger and are shaped to allow a current in them to produce an axial force with respect to the rings of magnets. A set of φ-axis coils (for rotational movement) have longitudinal axes that are parallel to the axis of the plunger and are sized to allow current in them to impel the columns of magnets. Part of the external surface of the plunger has a grid scale, which is encoded by Z-axis and φ-axis optical pickups to provide position information to a controller.
Ginkgo Diterpene Lactone Meglumine Injection 25mg/5ml,once/day from Day 1 to Day 14. The injection was diluted with 250ml physiological saline,intravenous drip for about 3 hours;combined with Acetylsalicylic acid (Aspirin) given at a dose of 100 mg per day for 90 days.
In preparing a granular laxative exhibiting retarded imbibition towards digestive juices, from gums containing mannogalactan hemicellulose, e.g. carob, garrofin or guar gum, the powdered endosperms of seeds containing the gums, e.g. algarobilla seeds, are mixed with water to form a soft, plastic, uniform mass which is granulated and gradually dehydrated, e.g. by drying in air or vacuum at temperatures not exceeding 110 DEG  C.  Granulation may be carried out under slight pressure, e.g. 2 to 3 kg/cm2, when the quantity of water used is 70 per cent. or more by weight of the powdered endosperms, and at great pressure, e.g. over 35 kg/cm2, when the amount of water is between 70 and 30 per cent. or when it is 30 per cent. or less and small quantities, e.g. 5 per cent. karaya gum, are added.  The dried granules may be coated with a hydrophylic or absorbent coating, e.g. of karaya gum.  They may be reduced to a size of 5 mm. or less for use in capsules.  The granules may be compressed into tablets without using agglutinants.  Phenolphthalein, belladonna, bile salts and hormones may be added to the gums before they are made into the plastic mass.ALSO:In preparing a granular laxative, exhibiting retarded imbibition towards digestive juices, from gums containing mannogalactan hemicellulose, e.g. carob, garrofin or guar gum, the powdered endosperms of seeds containing the gums, e.g. algarobilla seeds, are mixed with water to form a soft, plastic, uniform mass which is granulated and gradually dehydrated, e.g. by drying in air or vacuum at temperatures not exceeding 110 DEG C. Granulation may be carried out under slight pressure, e.g. 2 to 3 kg/cm2, when the amount of water used is 70 per cent or more by weight of the powdered endosperms, and at great pressure, e.g. over 35 kg/cm2, when the amount of water is between 70 and 30 per cent or when it is 30 per cent or less and small quantities, e.g. 5 per cent, of karaya gum are added.  The dried granules may be coated with a hydrophylic or absorbent coating, e.g. of karaya gum, to facilitate oral administering.  The granules may be reduced to a size of 5 mm. or less for use in capsules.  They may be compressed into tablets without using agglutinants.  Phenolphthalein, belladonna, bile salts and hormones may be added to the gums before they are made into the plastic mass.
A three-lowering tea (lowering blood sugar, pressure and lipid) and its raw material includes dogwoof fruit, Radix Polygoni Multiflori, cassia seed, Lycium chinensis, Radix Puerariae, haw and tea leaf. During its preparation, dogwood fruit is reflux-extracted with ethanol and then is filtered to obtain the filtrate  which is concentrated into dense ointment, with ethanol being recovered. Radix Polygoni Multiflori, cassia seed and Radix Puerariae are processed through the same steps to obtain one other kind of dense ointment. Lycium chinense and haw are decocted with water and filtered to obtain filtrate which is also concentrated into a third dense ointment. All the three ointments are mixed, the mixture after being diluted with water is sprayed onto tea leaf while stirring, and the sprayed tea is dried by depressurization at 60 deg.c, and packaged. The invented tea has excellent effects of reducing blood sugar, pressure and lipid.
OBJECTIVE: to validate with experts the content of a mobile application to guide patients with neurological dysfunction of the lower urinary tract.
METHOD: methodological study. For content validation, 81 specialist nurses took part. The data collection instrument was designed in the form of an electronic form, and included assessments of the application's objectives, content, language, relevance, functionality and usability. The data was submitted to descriptive and inferential statistical analysis, based on the measurement of the Content Validity Index.
RESULTS: the overall content validity index of the prototype application was 0.98. The lowest item (0.93) was related to the adequacy of the font size, and the highest module (1) was associated with usability, showing ease in handling the application. The experts recommended correcting spelling and grammar, as well as adding and minimizing information, standardizing language, among others.
CONCLUSION: the content of the MeduLar sem Medo ® mobile app was validated with excellence by specialists, and presented important resources for teaching urinary dysfunction control and adherence to rehabilitation. With these results, it is possible to envision the next stages of validation, with application in the populations for which it is intended and incorporation of this care technology into the Unified Health System.
The benefits of breastfeeding for both mother and neonate have been well documented and extensively researched. Breastfeeding rates remain suboptimal despite known advantages including reduced lifetime risk of maternal ovarian cancer, more rapid return to pre-gestational weight, improvement in maternal/neonatal bonding, reduction in neonatal allergic/immunologic conditions. Both non-modifiable and modifiable factors affecting a mother's decision regarding breastfeeding have been identified. Modifiable factors include breastfeeding knowledge, self-efficacy, and confidence. Breastfeeding self-efficacy has been positively correlated with breastfeeding duration. There is a lack of local data on breastfeeding rates, duration, and self-efficacy in the Augusta University women's health population as well as a lack of documented improvement of these factors following educational programs. Our study aims to create a program that is easily accessible and available to our patient population in the form of a free application available on Apple devices capable of accessing the internet (e.g., i-phone, i-pad, etc.). This study will be a randomized control trial. The intervention group will have access to the application while the control group will not. Our hypothesis is that the application will improve long-term breastfeeding rates, duration, and self-efficacy if offered to patients at 32 through 36 weeks gestation. This will be assessed by comparing initial self-efficacy survey results with survey results at 12 months postpartum for the intervention versus control groups. We will also measure breastfeeding duration during the first 12 months postpartum and exclusive breastfeeding rates at 6 months postpartum.
This will be a descriptive 4 month study of standard care practice. Patients who meet the inclusion / exclusion criteria for study will be enrolled (Waiver of informed consent is requested) and followed for a maximum of 28 days. The type and frequency of progressive mobility orders, whether or not progressive mobility steps are being taken by the nursing teams, define what steps patients are receiving, and record time to first weight bearing will be recorded. Weight bearing will be defined as standing for at least 1 minute. ICU LOS, Ventilator Days will be assessed at ICU discharge for study patients. Barriers to PM procedures will also be assessed.
OBJECTIVE: Refractory status epilepticus (RSE) treated with anesthetic agents can be associated with complications including respiratory depression and hypotension. Ketamine is an emerging RSE treatment, but optimal dosing and timing are unknown. We studied provider attitudes and practices regarding the use of ketamine for RSE.
METHODS: A literature review informed the creation of the survey, developed by professionals in epilepsy, pharmacy, and neurocritical care. The survey was distributed to members of the Critical Care EEG Monitoring and Research Consortium, Neurocritical Care Society, American Academy of Neurology Synapse community, American Epilepsy Society, and the Canadian League Against Epilepsy. Descriptive statistics were calculated.
RESULTS: There were 109 respondents. First-line agents for RSE were midazolam (53%), propofol (42%), pentobarbital (2%), and ketamine (1%). Reasons for ketamine use included failure of midazolam/propofol to control seizures (81%) or hypotension on another anesthetic (35%). Perceived contraindications included hypertension (37%), elevated intracranial pressure (24%), and heart failure (18%). Perceived benefits included decreased use of vasopressors (53%) and more rapid RSE control when used adjunctively (49%). Routine ketamine users often treated more than 10 RSE cases per year, worked as intensivists or at academic institutions. Of the respondents, 59% found ketamine useful for RSE and 94% were interested in learning more about its use.
CONCLUSIONS: Although most participants found ketamine helpful for RSE, it is mainly used as a second-line agent adjunctively with midazolam or propofol. Perceived ketamine benefits included decreased need for hemodynamic support and more rapid seizure control when used in conjunction with other anesthetics. Perceived contraindications centered on cardiac and intracranial pressure concerns.
Patients receive cetuximab IV over 60-120 minutes on days -28, -21, -14, -7 of weeks -4 to -1. Patients then receive cetuximab IV on days 1, 8, 15, and 22 and TLR8 agonist VTX-2337 SC on days 1, 8, 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Methods, systems and non-transitory computer readable media for automated workflow management for sleep quality are presented. A subject in a resting state is monitored using one or more sensors for acquiring one or more physiological parameters. A phase of sleep of the subject at a specific time using the physiological parameters is detected and inferred. Further, a recuperative benefit of the detected sleep phase is estimated. Additionally, it is determined is if an activity in a patient care workflow scheduled proximate to the specific time hinders sleep of the subject. The patient care workflow is then automatically reconfigured if scheduled activity hinders patient sleep, if the determined recuperative benefits exceed a designated threshold and/or if a proposed reconfiguration satisfies one or more designated criteria accounting for both restorative benefits to the patient and objectives of competing care delivery activities for both a given patient and a department.
Nonsymbiotic phytoglobins (nsHbs) are a diverse superfamily of hemoproteins grouped into three different classes (1, 2, and 3) based on their sequences. Class 1 Hb are expressed under hypoxia, osmotic stress, and/or nitric oxide exposure, while class 2 Hb are induced by cold stress and cytokinins. Both are mainly six-coordinated. The deoxygenated forms of the class 1 and 2 nsHbs from A. thaliana (AtHb1 and AtHb2) are able to reduce nitrite to nitric oxide via a mechanism analogous to other known globins. NsHbs provide a viable pH-dependent pathway for NO generation during severe hypoxia via nitrite reductase-like activity with higher rate constants compared to mammalian globins. These high kinetic parameters, along with the relatively high concentrations of nitrite present during hypoxia, suggest that plant hemoglobins could indeed serve as anaerobic nitrite reductases in vivo. The third class of nsHb, also known as truncated hemoglobins, have a compact 2/2 structure and are pentacoordinated, and their exact physiological role remains mostly unknown. To date, no reports are available on the nitrite reductase activity of the truncated AtHb3. In the present work, three representative nsHbs of the plant model Arabidopsis thaliana are presented, and their nitrite reductase-like activity and involvement in nitrosative stress is discussed. The reaction kinetics and mechanism of nitrite reduction by nsHbs (deoxy and oxy form) at different pHs were studied by means of UV-Vis spectrophotometry, along with EPR spectroscopy. The reduction of nitrite requires an electron supply, and it is favored in acidic conditions. This reaction is critically affected by molecular oxygen, since oxyAtHb will catalyze nitric oxide deoxygenation. The process displays unique autocatalytic kinetics with metAtHb and nitrate as end-products for AtHb1 and AtHb2 but not for the truncated one, in contrast with mammalian globins.
The present disclosure is directed towards systems and methods built for predictively timing the inflation and/or deflation of an intra-aortic balloon pump. A controller operates in three states: (1) initialization state, (2) learning state, and (3) peak detection state. The controller decomposes a patient's electrocardiogram signal to a power signal. It then learns characteristics of the patient's electrocardiogram signal during the learning state and computes adaptive threshold parameter values. During the peak detection state, the controller applies the learnt threshold parameter values on a current electrocardiogram signal to identify occurrence and timings of R peaks in the electrocardiogram signal. The R-to-R peak timings are then used to trigger inflation of an intra-aortic balloon pump.
Mindfulness Based Cognitive Therapy is a manualized, group skills training program (Segal et al., 2013) that is based on an integration of aspects of cognitive therapy for depression (Beck, 1979) with components of the mindfulness-based stress reduction program (Kabat-Zinn, 1990). Patients participate in 8 weekly sessions, each of which incorporates didactic and experiential learning, along with home practice of mindfulness skills taught in the program.
Staphylococcus aureus (SA) is a ubiquitous bacterium, part of the human commensal flora. The mucosa of the anterior nasal cavities represents the preferred site of colonization of SA. The SA ST398 clone, belonging to CC 398, was initially described as a zoonotic agent initially identified in France and the Netherlands. In fact, ST398 strains are separated into two distinct populations: a methicillin-resistant SA population (SAMR) with notion of contact with animals and a more virulent methicillin-sensitive SA population (SAMS) than its counterpart, isolated from serious human infections and without notion of exposure to farm animals. Recently, we have shown that, in SA bacteremia, all strains of SA ST398 are sensitive to methicillin and that the prevalence of ST398 among all SAMS responsible for bacteremia at Besançon University Hospital increased between 2009 and 2014, increased from 4 to 15%. However, we were unable to study nasal colonization to support the mode of acquisition of SA ST398 (community vs. healthcare acquisition).
1354525 Inducing diuresis : calcitonin compositions ARMOUR PHARMACEUTICAL CO 19 April 1971 [17 April 1970] 26563/71 Heading A5B Diuresis of sodium acid water without excessive potassium depletion is obtained by administering to non-human animals an effective quantity (e.g. 0.1 to 50 micrograms/Kg body weight of natural or synthetic fish ultimobronchial calcitorin having, in the substantially pure state, a potency of 3500 MRC units. Compositions which may be used may be in conventional forms suitable for oral, parenteral, topical, intravaginal and rectal administration and may contain conventional diluents, carriers and excipients. A method of obtaining suitable calcitonin (which in substantially pure form should have a potency of 3500 MRC units per mg) comprises homogenizing ultimobronchial tissue with 0.1N HCl, centrifuging, subjecting the extract to ultracentrifugation, lyophilising the supernatant, taking up in formic acid, adding trichloracetic acid, allowing to stand removing the precipitate, treating with an ion exchange resin in acetate gauge form to remove acid, diluting and lyophilising. Further purification may be by fractionation on "Sephadex" (Trade Mark) and C.M. "Sephadex" columns.
Dental ceramic is anisotropic and contains more than 90 wt.% hydroxylapatite (Ca5(PO4)3OH).  Independent claims are also included for:  (a) a process for the production of the dental ceramic comprising precipitating at least one calcium phosphate compound from an aqueous or organo-aqueous solution to form a precipitate; optionally washing, drying and crushing the precipitate; pressing to form a green body; and sintering. The Ca/P atomic ratio is 1.66-1.68; and  (b) a crystalline hydroxylapatite having rod-like crystals with a length of 70-1000 nm and a thickness of 7-500 nm.  Preferred Features: The refractive index in the region of the visible light is anisotropic and the green body and/or the sintered body have a double refraction. The difference in the refractive index  DELTA n \- 1 x 10<-4>, especially \- 2 x 10<-3>. The anisotropy is vertical to a given axis. The amount of tricalcium phosphate and/or other sparingly soluble phosphate is not more than 4%.
According to the National Medical Products Administration (NMPA) Guidance on Proton and Carbon Ion treatment system clinical evaluation and clinical trial, the participants with disease control should be at least 95%. The primary safety endpoints is that participants with Common Terminology Criteria for Adverse Events (CTCAE) grade 3 toxic reaction should be lower than 5%, CTCAE grade 4 and 5 toxic reaction rate is 0%. Therefore, the clinical trial did not have a control group, but using single-arm objective performance criteria.
The propofol infusion rate is adjusted manually in a pump by the investigator to maintain BIS between 40 and 60. For this titration it is necessary continuous monitoring, clinical experience, and pharmacokinetic/pharmacodynamic knowledge.
The invention relates to a personal care product for alleviating skin dryness, includes facial skin dryness, breast skin dryness and vulval dryness and for restoring vaginal flora, acidic pH in the vagina, and vaginal health. Embodiments of the personal care product include a formulation including at least about 83 wt. % plant-based glycerides; from about 0.05 wt. % to about 0.15 wt. % sodium hyaluronate; and from about 0.01 wt. % to about 1.5 wt. % sea buckthorn powder. Another embodiment includes a personal care product including at least 55 wt. % plant-based glycerides and from about 20 wt. % to about 42 wt. % sucrose. The personal care product may also include shea olein. The person care product is substantially free of added water, alcohol, synthetic chemical, anti-microbial agent, and synthetic hormone.
This is a randomized, double-blind, multicenter phase II clinical trial. In the trial, post-allo-HSCT patients with signs of bone marrow engraftment and without evidence of CMV reactivation will be enrolled. All enrolled patients will be monitored for their blood CMV DNA copy numbers by Q-PCR and safety throughout the trial. In addition to their routine post-allo-HSCT care, eligible patients will receive imatinib (100mg/tablet, 2 tablets daily) or placebo (2 tablets daily) administration after myeloid engraftment (defined as absolute neutrophil count higher than 500 for three consecutive days). While receiving the trial therapy, patients will have a regular CMV surveillance every week by the quantification of plasma CMV DNA copies. During the administration of the investigational drugs, other concomitant anti-CMV prophylaxis treatments are prohibited. When a patient has any signs suggesting CMV infection that the treating physician determines that an anti-CMV therapy is indicated, the patient will be defined as failure of prophylaxis for the efficacy evaluation. Whether the conventional anti-CMV therapy is started or not, the investigational drugs with imatinib or placebo will be continued till at least Day+100 unless the patient is defined as prophylaxis failure or withdraws from the study including personal reasons, early mortality, disease recurrence after transplantation, pregnancy, or the investigator decides that the subject should be withdrawn for safety reasons or physical conditions.